Phathom Pharmaceuticals (PHAT)

• Market cap: $1.25B
• 1 day: -0.57%
• 5 days: 7.14%
• 1 month: 15.75%
• 3 months: 49.07%
• 6 months: 83.87%
• Year to date: 139.56%
• 1 year: 116.79%
• 5 years: -48.58%
• 10 years: -28.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 427